anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
High viral titers of infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been detected in human corpses long after death. However, little is known about the kinetics of infectious SARS-CoV-2 in corpses. In this case series study, we investigated the postmortem kinetics of infectious SARS-CoV-2 in human corpses by collecting nasopharyngeal swab samples at multiple time points from six SARS-CoV-2-infected patients after their death. SARS-CoV-2 RNA was detected by quantitative reverse transcription-polymerase chain reaction from nasopharyngeal swab samples collected from all six deceased patients. A viral culture showed the presence of infectious virus in one deceased patient up to 12 days after death. Notably, this patient had a shorter time from symptom onset to death than the other patients, and autopsy samples showed pathological findings consistent with viral replication in the upper respiratory tract. Therefore, this patient died during the viral shedding phase, and the amount of infectious virus in the corpse did not decrease over time up to the date of autopsy (12 days after death). The findings of this study indicate that the persistence of SARS-CoV-2 in corpses can vary among individuals and may be associated with the stage of the disease at the time of death. These important results complement many previously reported findings on the infectivity of SARS-CoV-2 at postmortem.
Patients undergo leukapheresis 10 days prior to first injection. Patients receive ppDC ID divided in both arms with poly ICLC IM on day -10 and nivolumab IV and ipilimumab IV on day -9 prior to standard of care surgical resection.
PURPOSE:To obtain an application agent, containing a drug uniformly in a high concentration, and having improved absorbability through the skin, by forming a pressure-sensitive adhesive layer containing the drug. CONSTITUTION:An application agent obtained by adding a drug, e.g. a hypnotic such as phenobarbital, anti-inflammatory agent such as cortisone or psychotropic agent such as diazepam, in a saturation solubility or more to an acrylic high polymer solution having hydrophilic groups, e.g. consisting essentially of a methacrylic ester, adding a poor solvent for the above-mentioned acrylic high polymer to the resultant solution, mixing them, depositing the above-mentioned acrylic high polymer partially as fine particles, and forming a pressure-sensitive adhesive layer on the surface of a support, e.g. polyethylene, with the resultant suspension containing the above-mentioned drug and part of the acrylic high polymer as fine particles, and having high bioavailability. The amount of the drug to be used is 0.1-200pts.wt. based on 100pts.wt. acrylic high polymer.
NEW MATERIAL:The peptide of formula I - formula V. USE:Diagnosis of the infection with human leukemia virus, and diagnosis and research of mature T-cell leukemia, lymphoma and related diseases such as adult T-cell leukemia, dermatic T-cell lymphoma, etc. The peptide of formula I -V is used as a hapten for the preparation of antigen, and an antibody having specific reactivity to virus-relating protein is produced by the use of said antigen. The specific antibody can be used for the chromatographic purification of virus-relating proteins and various immunoassay of virus-relating protein by bonding e.g. with a carrier for affinity chromatography. PREPARATION:The peptide of formula I -V is produced by conventional peptide synthesis process, e.g. azide process, chloride process, acid anhydride process, etc. Amino acids are condensed one by one to the terminal amino acid or several fragments of the peptide are coupled with each other by solid-phase synthesis or liquid-phase synthesis.
PROBLEM TO BE SOLVED: To obtain a composition containing a reducing thio compound, an oleophilic substance and a cationic polymer and giving excellent wave effect, combing smoothness and luster to the hair without damaging the hair even by repeating the treatment. SOLUTION: This composition contains (A) 2.5-15wt.% of a reducing thio compound (e.g. thioglycolic acid) as a reducing agent in terms of free thioglycolic acid, (B) 0.05-5wt.% of an oleophilic substance selected from natural or synthetic oil or oil and fat (e.g. avocado oil or polyethylene glycol), an aliphatic alcohol and a fatty acid ester (e.g. myristyl alcohol) and (C) 0.1-5wt.% of a cationic polymer. The composition is properly compounded further with an alkalizing agent, a surfactant, a polymer, etc., and used in the form of an (aqueous) solution, emulsion, cream, foamable agent, etc.
The means is made in the form of solid gelatine capsules and shall find application as additive to the daily diet. It is recommended for increasing the organism resistance against atherosclerosis, in cardiovascular disorders, overweight and for maintaining good vision, including in diabetic retinopathy. It is used for the prophylactics of malignant cell alterations, varicose veins, as well as of inflammation such as arthritis and allergies. The solid gelatine capsules are homogenous mixture of dry extract of grape seeds and mixture of vitamins A, C and E, and the microelements of iron, manganese and zinc, with the following content of the components, in wt. %: dry extract of grape seeds from 28.12 to 34.37, mixture of vitamins and microelements: vitamin A 0.17-0.20, vitamin C from 11.25 to 13.75, vitamin E 2.25-2.75, iron (sulphate) 0.05-0.07, manganese (sulphate) 0.05-0.07, zinc (sulphate) 0.011-0.013, mannitol 28.12 to 34.37, lactic sugar 5.62-6.87, talcum from 11.24 to 13.74, magnesium stearate 1.68-2.06 and aerasil 1.12-1.37. 3 claims
Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
Enalaprilat injection results in the reduction of both supine and standing systolic and diastolic blood pressure, usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be anticipated in volume-depleted patients (see WARNINGS). The onset of action usually occurs within fifteen minutes of administration with the maximum effect occurring within one to four hours. The abrupt withdrawal of enalaprilat has not been associated with a rapid increase in blood pressure.

The duration of hemodynamic effects appears to be dose-related. However, for the recommended dose, the duration of action in most patients is approximately six hours.

Following administration of enalapril, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension.
FIELD: pharmaceutical industry. ^ SUBSTANCE: pharmaceutical composition represents a minitablet or pellet, covered with an isolating layer and enteric cover. The minitablet or pellet contains a pH-dependent medical product, preferably, dipiridamol, and the Ç modifier, chosen of the group consisting the following components: lemon acid, fumaric acid, amber acid, adipic acid and maleic acid. The isolating layer includes polymer, softener and the agent reducing stickiness, and separates a minitablet or pellet from enteric covering. The Ç modifier ratio to the pH-dependent medical product is from 0,2:1 to 2:1. The full liberation of the medical product from the pharmaceutical composition occurs simultaneously with the Ç modifier liberation during the time periodfrom 1 till 4 hours. ^ EFFECT: invented pharmaceutical compositions are characterized by decrease in variability and bioavailability increase in the body of one patient or more patients. ^ 7cl, 3 dwg, 7 ex
Worldwide, myocardial infarction (MI) is the leading cause of death and disability-adjusted life years lost. Recent researches explored new methods of detecting biomarkers that can predict the risk of developing myocardial infarction, which includes identifying genetic markers associated with increased risk. We induced myocardial infarction in mice by occluding the left anterior descending coronary artery and performed TTC staining to assess cell death. Next, we performed ChIP assays to measure the enrichment of histone modifications at the promoter regions of key genes involved in mitochondrial fission. We used qPCR and western blot to measure expression levels of relative apoptotic indicators. We report that miR-181a inhibits myocardial ischemia-induced apoptosis and preserves left ventricular function after MI. We show that programmed cell death protein 4 (PDCD4) is the target gene involved in miR-181a-mediated anti-ischemic injury, which enhanced BID recruitment to the mitochondria. In addition, we discovered that p53 inhibits the expression of miR-181a via transcriptional regulation. Here, we discovered for the first time a mitochondrial fission and apoptosis pathway which is controlled by miR-181a and involves PDCD4 and BID. This pathway may be controlled by p53 transcriptionally, and we presume that miR-181a may lead to the discovery of new therapeutic and preventive targets for ischemic heart diseases.
Control group does not receive neuropsychological rehabilitation or any other intervention during the first 5 months. After the control period they will be randomized to receive either individual or group based rehabilitation.
Prospective sample collection from participants treated with HIPEC combined PD1/PDL1inhibitor at Affiliated Cancer Hospital \& Institute of Guangzhou Medical University under standard of care treatment. Blood and tissue samples will be collected prior to initiation of conversion therapy. And thereafter at the four time points: before and after surgery(±7 days), before the start of the second cycle of adjuvant, tumour progression, blood sample will be collected too.
FIELD: medicine. ^ SUBSTANCE: invention concerns medical equipment, namely to endoluminal prostheses, such as a coronary stent. The stent for implantation at least partially, in a blood vessel in contact to a blood vessel wall, contains at least one released medical agent. The released medical agent contains melatonin or a medical product received from the melatonin. The medical agent is applied on the surface of a stent which does not have coverings. ^ EFFECT: invention provides prevention of an inflammation caused by a trauma, caused at the expense of stent implantation; the prevention neointimal proliferation of a tissue and growing in a tissue; controlled remission completely a biocompatible medical product in a current of several weeks. ^ 6 cl, 1 tbl
CFIRL is a long noncoding RNA (lncRNA), we previously identified as the most significantly upregulated lncRNA in the failing hearts of patients with dilated cardiomyopathy (DCM). In this study, we determined the function of CFIRL and its role in DCM. Real-time polymerase chain reaction and in situ hybridization assays revealed that CFIRL was primarily localized in the nucleus of cardiac fibroblasts and robustly increased in failing hearts. Global knockdown or fibroblast-specific knockout of CFIRL attenuated transverse aortic constriction (TAC)-induced cardiac dysfunction and fibrosis in vivo. Overexpression of CFIRL in vitro promoted fibroblast proliferation and aggravated angiotensin II-induced differentiation to myofibroblasts. CFIRL knockdown attenuated these effects. Mechanistically, RNA pull-down assay and gene expression profiling revealed that CFIRL recruited ENO1, a newly identified noncanonical transcriptional factor, to activate IL-6 transcription. IL-6 exerted a paracrine effect on cardiomyocytes to promote cardiac hypertrophy, which can be prevented by CFIRL knockdown. These findings uncover the critical role of CFIRL, a fibroblast-associated lncRNA, in heart failure by facilitating crosstalk between fibroblasts and cardiomyocytes. CFIRL knockdown might be a potent strategy to prevent cardiac remodeling in heart failure, particularly in DCM.
The invention relates to the field of tumor treatment, in particular to an anti-tumor effect of a lipid regulator Ezetimibe (Ezetimibe). The invention discloses an anti-tumor effect of ezetimibe in inhibiting proliferation, migration and invasion of tumor cells and inducing apoptosis. The invention detects the influence of ezetimibe on the activity of various tumor cells, and finds that the concentration of ezetimibe is dependent on the inhibition of the growth of the tumor cells. After ezetimibe with the concentrations of 0, 5, 10 and 20 mu M is selected to treat the tumor cells for a certain time, the changes of the migration, invasion and apoptosis conditions of the tumor cells are evaluated, and the ezetimibe is found to have strong inhibition effects on the migration and invasion of the tumor cells and have certain induction effects on the apoptosis of the tumor cells. The ezetimibe is proved to be capable of inhibiting the survival, migration and invasion of tumor cells and inducing the apoptosis of the tumor cells, thereby generating multi-mechanism anti-tumor effect. The invention provides a basis for the application of ezetimibe in the field of tumor treatment.
PURPOSE:To obtain the low polishing-high cleaning effect of a polishing base material such as dentifrice and lapping agents by applying a baking process at 70-1,200  deg.C to calcium hydrogenphosphate anhydride containing crystallites of sizes within a predetermined value measured via an X-ray diffraction method. CONSTITUTION:Calcium hydrogenphosphate anhydride containing crystallites of such a mean size as 200-3,500 angstrom or preferably 300-3,000 angstrom measured via an X-ray diffraction method is baked at temperature of 700-1,200  deg.C, thereby forming a polishing base material. This base material is cracked into grains of suitable sizes so that a mean grain diameter measured via a laser beam scattering method will be 2-3mum or preferably 5-25mum. In this case, the material when used as a polishing agent of dentifrice composition, is baked at a temperature level of about 700  deg.C or below. For use as a lapping agent for an IC wafer and the like, the material is baked at a level over 700  deg.C. In this way, low polishing-high cleaning effect becomes available and the material so processed is stable and water suspension type, thereby enabling preventing the effluence of calcium ion as far as practicable.
ICON8 is a three-arm, three stage trial. Patients will be randomised in a 1:1:1 ratio. Patients in arm 1 (control arm) will receive weekly carboplatin and paclitaxel on day 1 of a 21-day cycle for 6 cycles. Patients in arm 2 will receive carboplatin on day 1 and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles. Patients in arm 3 will receive dose-fractionated weekly carboplatin and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles.

The trial will have three planned stages. Stage 1 will be conducted to confirm feasibility and safety of protocol treatment in all patients and separately in the Delayed Primary Surgery (DPS) patients. The outcome measure for stage 2 will be 9-month progression-free survival (PFS) rate. The primary outcome measures for stage 3 will be PFS and overall survival and secondary outcomes will be toxicity, Quality of Life and Health Economics. If pre-defined levels of deliverability, at stage 1, or activity, at stage 2, are not met then the research arms will be reconsidered.
Caspases are enzymes with protease activity. Despite being known for more than three decades, caspase investigation still yields surprising and fascinating information. Initially associated with cell death and inflammation, their functions have gradually been revealed to extend beyond, targeting pathways such as cell proliferation, migration, and differentiation. These processes are also associated with disease mechanisms, positioning caspases as potential targets for numerous pathologies including inflammatory, neurological, metabolic, or oncological conditions. While in vitro studies play a crucial role in elucidating molecular pathways, they lack the context of the body's complexity. Therefore, laboratory animals are an indispensable part of successfully understanding and applying caspase networks. This paper aims to summarize and discuss recent knowledge, understanding, and challenges in caspase knock-out mice.
The invention relates to a difunctional vaccine combining virus-like particles and monoclonal antibodies for infectious bursal disease, and belongs to the field of biological pharmacy. Genetic engineering technology is utilized to construct a recombinant baculovirus containing a virulent strain VP2 of the infectious bursal disease virus; and an insect cell culture method is employed for high-efficiency expression of a virus-like particle recombinant VP2 protein. A lymphocyte hybridomas technology is utilized to establish hybridoma cell strains secreting monoclonal antibodies against infectious bursal disease virus; and a cell culture or BALB/C ascites induction method is employed to prepare the monoclonal antibodies. The virus-like particle recombinant VP2 protein and the monoclonal antibodies are prepared into a vaccine combining infectious bursal disease virus-like particle and monoclonal antibody for infectious bursal disease through a specific method. The novel vaccine has dual functions of prevention and treatment on infectious bursal disease, has better effect than an individual vaccine and / or antibody. In addition, the novel vaccine is convenient for application and has great production and application values.
BACKGROUND: Autism spectrum disorder (ASD) is a disease characterized by social disorder. Recently, the population affected by ASD has gradually increased around the world. There are great difficulties in diagnosis and treatment at present.
METHODS: The ASD datasets were obtained from the Gene Expression Omnibus database and the immune-relevant genes were downloaded from a previously published compilation. Subsequently, we used WGCNA to screen the modules related to the ASD and immune. We also choose the best combination and screen out the core genes from Consensus Machine Learning Driven Signatures (CMLS). Subsequently, we evaluated the genetic correlation between immune cells and ASD used GNOVA. And pleiotropic regions identified by PLACO and CPASSOC between ASD and immune cells. FUMA was used to identify pleiotropic regions, and expression trait loci (EQTL) analysis was used to determine their expression in different tissues and cells. Finally, we use qPCR to detect the gene expression level of the core gene.
RESULTS: We found a close relationship between neutrophils and ASD, and subsequently, CMLS identified a total of 47 potential candidate genes. Secondly, GNOVA showed a significant genetic correlation between neutrophils and ASD, and PLACO and CPASSOC identified a total of 14 pleiotropic regions. We annotated the 14 regions mentioned above and identified a total of 6 potential candidate genes. Through EQTL, we found that the CFLAR gene has a specific expression pattern in neutrophils, suggesting that it may serve as a potential biomarker for ASD and is closely related to its pathogenesis.
CONCLUSIONS: In conclusion, our study yields unprecedented insights into the molecular and genetic heterogeneity of ASD through a comprehensive bioinformatics analysis. These valuable findings hold significant implications for tailoring personalized ASD therapies.
An exposure-response analysis encompassing doses of atomoxetine (0.5, 1.2 or 1.8 mg/kg/day) or placebo demonstrated atomoxetine exposure correlates with efficacy as measured by the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator administered and scored. The exposure-efficacy relationship was similar to that observed between dose and efficacy with median exposures at the two highest doses resulting in near maximal changes from baseline [see Clinical Studies (14.2)]. 

     Cardiac Electrophysiology — The effect of atomoxetine on QTc prolongation was evaluated in a randomized, double-blinded, positive-(moxifloxacin 400 mg) and placebo-controlled, cross-over study in healthy male CYP2D6 poor metabolizers. A total of 120 healthy subjects were administered atomoxetine (20 mg and 60 mg) twice daily for 7 days. No large changes in QTc interval (i.e., increases >60 msec from baseline, absolute QTc >480 msec) were observed in the study. However, small changes in QTc interval cannot be excluded from the current study, because the study failed to demonstrate assay sensitivity. There was a slight increase in QTc interval with increased atomoxetine concentration.
Methods of the prophylaxis of the development of allergy in a patient at risk of sensitization to an antigen(s) or allergen(s) due to impaired gastrointestinal functions include administering a mast cell inhibitor, e.g., ketotifen, e.g., ketotifen fumarate. Methods for prophylactically treating, reducing, delaying or controlling gastrointestinal disorders include administering a mast cell stabilizer, e.g., ketotifen to a patient in need thereof. Pharmaceutical preparation, composition for use in methods described, are also disclosed. Also disclosed are methods of prophylaxis or treating gastrointestinal and esophageal inflammation, and methods for the prophylaxis of the development of additional allergies to a newly introduced substance in a patient with a preexisting allergy. Such methods include delivery of a mast cell stabilizer, e.g., ketotifen. Oral and topical administration are contemplated within the scope of the methods.
Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days, and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
New methods are disclosed for detecting cancer associated genes, and obtaining corresponding cDNA sequences. The methods involve supplying RNA preparations from control cells, and from a plurality of different cancer cells that share a duplicated or deleted gene in the same region of a chromosome. Amplified cDNA copies are displayed, and then selected based on differences in abundance of RNA between preparations. Optional additional screening steps involve surveying panels of cancer cells using the cDNA for RNA overabundance with or without gene duplication. The identified genes can be used in turn to develop materials and techniques for diagnosing and treating the underlying cancer. Four novel genes associated with cancer have been identified. In at least about 60 % of the breast cancer cell lines tested, RNA hybridizing with the cDNAs were substantially more abundant than in normal cells. Most of the cell lines also showed a duplication of the corresponding gene, which probably contributed to the increased level of RNA in the cell. However, for each of the four genes, there were some cell lines which had RNA overabundance without gene duplication. This suggests that the gene product is sufficiently important to the cancer process that cells will use several alternative mechanisms to achieve increased expression.
The invention relates to a hybrid antibacterial peptide and a preparation method and application thereof. The amino acid sequence of the hybrid antibacterial peptide is shown as SEQ ID NO. 6, and the nucleotide sequence of the gene for coding the hybrid antibacterial peptide is shown as SEQ ID NO. 5. The invention obtains the recombinant vector of expression cassettes with different copy numbers containing the coding heterozygous antibacterial peptide gene by constructing a multi-copy expression cassette expression vector in vitro, further obtains the yeast transformant of the recombinant vector containing the expression cassettes with different copy numbers, and efficiently expresses the gene in a host cell of pichia pastoris through methanol induction to obtain the heterozygous antibacterial peptide. The preparation method can efficiently prepare the hybrid antibacterial peptide, the culture condition is simple, the yield is high, the cost is low, and the obtained hybrid antibacterial peptide has a good antibacterial effect and is suitable for being used as antibacterial drugs, feed additives and the like.